Is there a domestic version of Axitinib and the latest news on domestic research and development progress?

Axitinib (Axitinib) is an oral small molecule tyrosine kinase inhibitor mainly used to treat malignant tumors such as renal cell carcinoma. Currently, axitinib is already on the market in China and has been included in the national medical insurance directory. Patients can obtain it through regular hospital pharmacies. Since the original research company of this drug is Pfizer, currently the main products sold in the domestic market are imported original research drugs, and there is no fully independently produced domestic version. However, as domestic pharmaceutical companies continue to deploy in the field of targeted drugs, related generic research and development is accelerating.

In recent years, many domestic pharmaceutical companies have begun to develop generic drugs of axitinib and have successively submitted applications for production or clinical trials. According to the latest news, some companies’ axitinib generics have entered the clinical research stage, and are expected to further reduce patient burden in terms of price and accessibility in the future. Although no domestically produced axitinib has yet been officially approved for marketing, its research and development progress has been significantly accelerated due to policy promotion, and domestically produced versions may gradually enter the market in the next few years.

Axitinib currently sold in China is an imported original drug with a price of approximately more than 4,000 yuan. Since it has been included in medical insurance, the actual payment amount of the patient will be significantly reduced. The specific price and reimbursement ratio need to be confirmed according to local medical insurance policies and hospital pharmacy information. In contrast, generic drugs on the foreign market, such as the Indian and Lao versions, cost around a few hundred yuan, and their ingredients and efficacy are basically the same as the original drugs. However, because cross-border procurement involves channel and compliance issues, patients should choose carefully.

If domestically produced axitinib is successfully launched in the future, the price is expected to drop significantly, and the drug's accessibility to patients will also be further improved. For patients currently taking medications, it is recommended to obtain original drugs through regular hospitals and pharmacies, and combine them with medical insurance reimbursement to reduce the financial burden. For patients who need to purchase drugs across borders, they should focus on the formal channels and safety of drugs. Before the domestic version is released, the imported original drug of axitinib is still the main clinical choice, and the acceleration of domestic research and development will become an important hope for patients to obtain more economical treatment.

Reference materials:https://www.drugs.com/